Drug intelligence / Profile preview

insulin isophane + insulin glulisine

Development stage
Phase 3
Lead developer
Sanofi
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

**Insulin isophane + insulin glulisine** is a combination of two insulins used for the treatment of diabetes mellitus. **Insulin isophane** (also known as NPH insulin) is an intermediate-acting human insulin that forms a depot at the injection site, releasing insulin slowly to provide basal glycemic control. **Insulin glulisine** is a rapid-acting insulin analog that is quickly absorbed after subcutaneous injection and is used to control postprandial blood glucose spikes. When combined, this regimen covers both basal and prandial insulin needs, potentially improving glycemic control over traditional combinations such as isophane with regular insulin. The mechanism of action for both components is to lower blood glucose by facilitating cellular uptake of glucose and inhibiting hepatic glucose output. This combination is not commercially available as a fixed premix, but clinical trials have investigated its efficacy when given as separate injections as part of a basal-bolus insulin regimen[2][5].

Brand names
Novolin NInsulatardInsuman BasalActraphaneRonulin NLupisulin NInsugen NDipusulin NHuminsulin NHumanext NWosulin NLentardJusline NGensulin NSciLin NProtaphane
02

Targets

INSR (Insulin receptor)IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on insulin isophane + insulin glulisine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin isophane + insulin glulisine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call